Skip to main content

Table 1 Demographics of total patient population

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

 

Total

BT-naïve

BT-experienced

ADL

IFX

SCK

UST

Sub

total

ADL

IFX

SCK

UST

Sub

total

ADL

IFX

SCK

UST

Sub

total

Number of patients

42

52

21

90

205

37

48

13

79

177

5

4

8

11

28

Average Age

50.0

46.2

45.4

46.8

47.1

50.9

46.0

46.2

46.5

47.3

43.4

47.5

44.3

48.4

46.2

% Female

7.1%

21.2%

33.3%

17.8%

18.1%

8.1%

20.8%

46.2%

20.3%

19.8%

0.0%

25.0%

12.5%

0.0%

7.1%

  1. ADL Adalimumab, IFX Infliximab, SCK Secukinumab, UST Ustekinumab